Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04505722 · ClinicalTrials.gov registry record · Phase 3
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
A Phase 3 study of Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 44,325
- Enrollment target
- 20
- Study locations
NCT04505722 is a Phase 3 study of Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 44,325 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT04505722, a Phase 3 study of Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 44,325 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Ad26.COV2.S
Study Locations (20)
California
- Anaheim Clinical Trials, LLC - Anaheim
- Ark Clinical Research - Long Beach
- Anthony Mills Medical, Inc - Los Angeles
- Stanford University Medical Center - Palo Alto
- UCSD Antiviral Research Center AVRC - San Diego
- Wr McCr Llc - San Diego
- VA Medical Center - San Francisco
Arizona
- Synexus Clinical Research US Inc - Glendale
- VA Medical Center - Phoenix
- Central Phoenix Medical Clinic - Phoenix
- Quality of Life Medical & Research Center, LLC - Tucson
- Synexus Clinical Research US Inc - Tucson
Alabama
- Synexus Clinical Research US Inc - Birmingham
- University of Alabama Birmingham - Birmingham
- Alabama Vaccine Research Clinic at UAB - Birmingham
- Optimal Research - Huntsville
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Central Arkansas Veterans Healthcare System - Little Rock
Colorado
- Childrens Hospital Colorado - Aurora
- Rocky Mountain Regional VA Medical Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44,325 participants |
| Start Date | 2020-09-07 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04505722
The ClinicalTrials.gov registry entry for NCT04505722 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 44,325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04505722 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT04505722 about?
NCT04505722 is a clinical study titled "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants". The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.
What is the current status of trial NCT04505722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 44,325 participants. The study started on 2020-09-07. Estimated completion is 2023-03-31.
What conditions does trial NCT04505722 study?
This clinical trial studies the following conditions: Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol.
What interventions are being tested in trial NCT04505722?
The interventions under investigation include: Placebo (OTHER), Ad26.COV2.S (BIOLOGICAL).
Who is sponsoring clinical trial NCT04505722?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04505722 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.